Определение варианта полиморфизма гена интерлейкина 28в как предиктора эффективности противовирусной терапии хронического гепатита с

The induction method for introducing of standard interferon-α (IFN-α) in combination with ribavirin in patients with chronic hepatitis C (CHC), although it does not apply to current international standards, is often used in the practice of medicine. The search of predictors antiviral therapy is conducted in recent years. Polymorphism rs12979860 and rs8099917 gene interleukin-28B (IL-28B) has a significant effect on the frequency of achieving sustained virological response (SVR) in the treatment with pegylated interferon. The aim of this study — to evaluate the effectiveness of the inductive method of introduction of IFN-α during combination antiviral therapy of CHC based on the patient´s IL-28B genotyping. Material and methods. We observed 89 patients with CHC treated with IFN-α in the induction mode in combination with ribavirin, lasting 24-48 weeks. Identification of single nucleotide polymorphisms (PEN) in rs12979860 and rs8099917 locus gene IL-28B was conducted in 29 patients using the «AmpliSens Genoscreen — IL 28V-FL» reagent kit in the viral hepatitis laboratory of the molecular diagnostic department. Results. SVR at week 24 of follow-up was achieved in 70,8% of treated patients. Genotypes rs12979860 CC and rs8099917 TT of IL-28B gene in a group of patients responding to treatment reported in 40 and 60%, respectively. In patients with HCV genotype 1 (HCV-1) the maximum frequency of virologic response rates were reported for patients with rs12979860 CC and rs8099917 TT (SVR — 83,3 and 54,5% respectively). Conclusion. Predictor of efficiency the inductive method of the use IFN-α with ribavirin for antiviral treatment CHC in patients with HCV-1 genotypes are CC rs12979860 and rs8099917 TT by IL-28B.